Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Voxel-wise case-control analysis of dose, linear energy transfer and symptomatic brainstem necrosis in pediatric brain tumors treated with proton therapy.

International journal of radiation oncology, biology, physics·2026
Same author

DENTALE: a validated Dentofacial EvaluatioN Tool to standardize radiological Assessment of Late dental and maxillofacial adverse Effects following treatment for pediatric rhabdomyosarcoma.

Frontiers in pediatrics·2026
Same author

Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1).

Theranostics·2026
Same author

Dose-effect analysis of facial bone morphology following radiation therapy for head and neck rhabdomyosarcoma.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Local Control of Bladder/Prostate Rhabdomyosarcoma: An Expert Consensus Guideline From the International Soft Tissue Sarcoma Consortium (INSTRuCT).

Pediatric blood & cancer·2026
Same author

Systematic review of facial deformation following paediatric head and neck radiation therapy: A call for standardised outcome assessment and dose-response evidence.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same journal

The skin microbiome-immune-barrier axis: implications for inflammatory skin disorders and immunotherapeutic strategies.

Immunotherapy·2026
Same journal

Utility of serum Krebs von den Lungen-6 and surfactant protein D levels for differential diagnosis of immune checkpoint inhibitor-related pneumonitis.

Immunotherapy·2026
Same journal

Anti-PD-(L)1 plus chemotherapy in advanced PD-L1-negative nonsquamous non-small cell lung cancer: a systematic review and meta-analysis.

Immunotherapy·2026
Same journal

Anti-TIGIT therapies in digestive cancers: from immune evasion to precision immunotherapy.

Immunotherapy·2026
Same journal

CAR cellular therapies for acute myeloid leukemia: current landscape and future directions.

Immunotherapy·2026
Same journal

Recent advances in bispecific natural killer cell engagers for cancer immunotherapy.

Immunotherapy·2026
See all related articles

Related Experiment Video

Updated: May 16, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Dendritic cell immunotherapy in soft tissue sarcoma.

Daniel J Indelicato1, Steven E Finkelstein

  • 1Department of Radiation Oncology, University of Florida Proton Therapy Institute, 2015 North Jefferson St, Jacksonville, FL 32206, USA. dindelicato@floridaproton.org

Immunotherapy
|November 15, 2012
PubMed
Summary
This summary is machine-generated.

Immunotherapy using dendritic cells shows promise for treating soft tissue sarcomas. Combining hypofractionated radiotherapy with dendritic cell therapy may enhance anti-tumor immune responses, offering new avenues for cancer treatment.

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

Related Experiment Videos

Last Updated: May 16, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

Area of Science:

  • Oncology
  • Immunology
  • Radiotherapy

Background:

  • Soft tissue sarcomas are rare, diverse tumors with limited treatment options for metastatic disease.
  • Conventional chemotherapy and targeted agents have shown limited efficacy in broad sarcoma populations.
  • Immunotherapy, focusing on T-cell responses to tumor antigens, is an emerging area of investigation.

Purpose of the Study:

  • To explore the potential of dendritic cell-based immunotherapy for soft tissue sarcomas.
  • To investigate the synergistic effects of hypofractionated radiotherapy and dendritic cell therapy.
  • To assess the broader applicability of these combined approaches in other cancer types.

Main Methods:

  • Review of animal models and human clinical trials involving dendritic cell immunotherapy in sarcoma.
  • Analysis of the impact of hypofractionated radiotherapy on dendritic cell function and apoptosis induction.
  • Exploration of potential synergistic mechanisms between radiotherapy and cellular immunity.

Main Results:

  • Dendritic cells have demonstrated the ability to induce effective anti-tumor immune responses in sarcoma models and patients.
  • Hypofractionated radiotherapy may enhance dendritic cell function, potentially through induced apoptosis.
  • A synergistic effect between radiotherapy and dendritic cell immunotherapy is suggested.

Conclusions:

  • Dendritic cell immunotherapy is a promising strategy for soft tissue sarcomas.
  • Combining hypofractionated radiotherapy with dendritic cell therapy may potentiate anti-tumor immunity.
  • Further multidisciplinary research is warranted to explore these synergistic effects in various cancer types.